PRPO — Precipio, Inc.

Is PRPO overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Strong Oversold As of November 17, 2026

Precipio, Inc. (PRPO) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Diagnostics & Research) last closed at $19.96. The rating moved from Overbought to Strong Oversold on November 17, 2026.

See all oversold Healthcare stocks →

AI analysis

Precipio appears to occupy a niche in diagnostics/specialty lab services that could benefit from shifts toward specialty distribution and higher-margin biopharma services, but there is significant uncertainty due to limited public filing analysis and absent social/research signals. Near-term market conditions are defensive, which tends to depress small-cap healthcare performance, while reimbursement policy changes and the need for financing or partnership execution are primary near-term constraints. Monitor forthcoming clinical readouts, partnership announcements, and any SEC filings for clearer visibility into cash runway and revenue cadence; without those, valuation and upside remain speculative.

Key factors

  • Limited public financial disclosure and absent recent EDGAR comparisons increase uncertainty about cash runway and profitability.
  • Niche diagnostics / specialty laboratory positioning could benefit from distributor shift toward specialty care and infusion channels.
  • Market environment is risk-off with defensive flows, reducing near-term upside for small-cap healthcare names.
  • Potential catalysts include new clinical data, commercialization partnerships, or specialty pharmacy/distributor arrangements.
  • Reimbursement and Medicare/Medicaid policy changes can materially affect revenue for diagnostic service providers.

Risks

  • Unclear financial health and potential need for dilutive financing given lack of recent filing analysis.
  • Reimbursement risk from Medicare Advantage / CMS program integrity actions and clawbacks that could compress margins.
  • High competitive pressure from larger diagnostics and pathology service providers with broader scale.
  • Operational execution risk for commercial rollouts, partnerships, or scaling laboratory services.
  • Low liquidity and elevated share volatility typical of micro/small-cap names, raising trading and holding risk.
  • Information gaps: no social sentiment or recent EDGAR comparisons available to validate market perception.

See today's live rating, score and targets

Members see the live hourly rating for PRPO — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.